Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back
Authors
Keywords
-
Journal
CA-A CANCER JOURNAL FOR CLINICIANS
Volume 64, Issue 6, Pages 422-444
Publisher
American Cancer Society
Online
2014-09-30
DOI
10.3322/caac.21252
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- How we manage autologous stem cell transplantation for patients with multiple myeloma
- (2014) M. A. Gertz et al. BLOOD
- Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results
- (2014) Graham H. Jackson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Best Treatment Strategies in High-Risk Multiple Myeloma: Navigating a Gray Area
- (2014) Giada Bianchi et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Progression–Related Death
- (2014) Philippe Moreau et al. JOURNAL OF CLINICAL ONCOLOGY
- Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data
- (2014) Antonio Palumbo et al. LANCET ONCOLOGY
- Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
- (2014) Lotfi Benboubker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
- (2014) Niccolo Bolli et al. Nature Communications
- Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
- (2014) D S Siegel et al. Blood Cancer Journal
- Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management
- (2013) S. Vincent Rajkumar AMERICAN JOURNAL OF HEMATOLOGY
- Trends in Use of and Survival after Autologous Hematopoietic Cell Transplantation in North America, 1995-2005: Significant Improvement in Survival for Lymphoma and Myeloma during a Period of Increasing Recipient Age
- (2013) Philip L. McCarthy et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
- (2013) Ayman Saad et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02
- (2013) X. Leleu et al. BLOOD
- A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance
- (2013) Z. Tian et al. BLOOD
- PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
- (2013) P. G. Richardson et al. BLOOD
- Carfilzomib
- (2013) K. M. Kortuem et al. BLOOD
- Genomic instability in multiple myeloma: mechanisms and therapeutic implications
- (2013) Paola Neri et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma
- (2013) Prashant Kapoor et al. JOURNAL OF CLINICAL ONCOLOGY
- International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease
- (2013) Evangelos Terpos et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma
- (2013) Jesús F. San-Miguel et al. JOURNAL OF CLINICAL ONCOLOGY
- Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study
- (2013) Andy C. Rawstron et al. JOURNAL OF CLINICAL ONCOLOGY
- Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
- (2013) Meletios Dimopoulos et al. LANCET ONCOLOGY
- Inhibition of HSP90 molecular chaperones: moving into the clinic
- (2013) Rocio Garcia-Carbonero et al. LANCET ONCOLOGY
- Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study
- (2013) A J Jakubowiak et al. LEUKEMIA
- Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients
- (2013) A K Nooka et al. LEUKEMIA
- Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms
- (2013) B A Walker et al. LEUKEMIA
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
- (2013) J. Kronke et al. SCIENCE
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
- (2013) G. Lu et al. SCIENCE
- Novel Agents for Multiple Myeloma to Overcome Resistance in Phase III Clinical Trials
- (2013) Robert Z. Orlowski SEMINARS IN ONCOLOGY
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
- (2012) D. S. Siegel et al. BLOOD
- IMWG consensus on maintenance therapy in multiple myeloma
- (2012) H. Ludwig et al. BLOOD
- A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide
- (2012) M. A. Dimopoulos et al. BLOOD
- Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma
- (2012) P. L. Bergsagel et al. BLOOD
- Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics
- (2012) A. J. Greenberg et al. BLOOD
- Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
- (2012) S. Kumar et al. BLOOD
- Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma
- (2012) Y.-T. Tai et al. BLOOD
- Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
- (2012) L. Santo et al. BLOOD
- Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment
- (2012) K E Armeson et al. BONE MARROW TRANSPLANTATION
- A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance
- (2012) Dharminder Chauhan et al. CANCER CELL
- Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial
- (2012) M. A. Dimopoulos et al. HAEMATOLOGICA
- Evolution of cellular immunotherapy: from allogeneic transplant to dendritic cell vaccination as treatment for multiple myeloma
- (2012) Jon Arnason et al. Immunotherapy
- The 39th David A. Karnofsky Lecture: Bench-to-Bedside Translation of Targeted Therapies in Multiple Myeloma
- (2012) Kenneth C. Anderson JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
- (2012) Pieter Sonneveld et al. JOURNAL OF CLINICAL ONCOLOGY
- Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
- (2012) Sagar Lonial et al. JOURNAL OF CLINICAL ONCOLOGY
- High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma
- (2012) G Bianchi et al. LEUKEMIA
- Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma
- (2012) J T Larsen et al. LEUKEMIA
- Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
- (2012) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Plasma Cell Myeloma and Related Neoplasms
- (2011) Robert B. Lorsbach et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Pathogenesis of Myeloma
- (2011) Kenneth C. Anderson et al. Annual Review of Pathology-Mechanisms of Disease
- Paraproteins of familial MGUS/multiple myeloma target family-typical antigens: hyperphosphorylation of autoantigens is a consistent finding in familial and sporadic MGUS/MM
- (2011) S. Grass et al. BLOOD
- Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
- (2011) K. Neben et al. BLOOD
- The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis
- (2011) G. J. Morgan et al. BLOOD
- International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation
- (2011) M. Cavo et al. BLOOD
- Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation
- (2011) E. Zamagni et al. BLOOD
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial
- (2011) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
- (2011) David H. Henry et al. JOURNAL OF CLINICAL ONCOLOGY
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
- (2011) Philippe Moreau et al. LANCET ONCOLOGY
- Initial genome sequencing and analysis of multiple myeloma
- (2011) Michael A. Chapman et al. NATURE
- Molecular chaperones in protein folding and proteostasis
- (2011) F. Ulrich Hartl et al. NATURE
- Diagnosis of Smoldering Multiple Myeloma
- (2011) S. Vincent Rajkumar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Deubiquitinases in cancer: new functions and therapeutic options
- (2011) J M Fraile et al. ONCOGENE
- The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation
- (2011) P. Walter et al. SCIENCE
- Molecular Imaging in Myeloma Precursor Disease
- (2011) Esther Mena et al. SEMINARS IN HEMATOLOGY
- Ultra High-Risk Myeloma
- (2011) H. Avet-Loiseau Hematology-American Society of Hematology Education Program
- XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments
- (2010) T. Bagratuni et al. BLOOD
- Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma
- (2010) J. Rosenblatt et al. BLOOD
- Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug
- (2010) J. Hu et al. BLOOD
- Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma
- (2010) I. Papandreou et al. BLOOD
- Lenalidomide mode of action: linking bench and clinical findings
- (2010) Faith Davies et al. BLOOD REVIEWS
- New Molecular and Biological Mechanism of Antitumor Activities of KW-2478, a Novel Nonansamycin Heat Shock Protein 90 Inhibitor, in Multiple Myeloma Cells
- (2010) T. Nakashima et al. CLINICAL CANCER RESEARCH
- Proteostenosis and plasma cell pathophysiology
- (2010) Simone Cenci et al. CURRENT OPINION IN CELL BIOLOGY
- Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study
- (2010) Meletios A. Dimopoulos et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study
- (2010) Pierre Wijermans et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial
- (2010) Jean-Luc Harousseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences
- (2010) Bart Barlogie et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
- (2010) Hervé Avet-Loiseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial
- (2010) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group
- (2010) Meletios A. Dimopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
- (2010) Gareth J Morgan et al. LANCET
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
- (2010) Michele Cavo et al. LANCET
- Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
- (2010) M Q Lacy et al. LEUKEMIA
- Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
- (2010) R A Kyle et al. LEUKEMIA
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- How I treat multiple myeloma in younger patients
- (2009) A. K. Stewart et al. BLOOD
- A monoclonal gammopathy precedes multiple myeloma in most patients
- (2009) B. M. Weiss et al. BLOOD
- CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy
- (2009) A. K. Azab et al. BLOOD
- Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
- (2009) O. Landgren et al. BLOOD
- The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
- (2009) G. Bianchi et al. BLOOD
- Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
- (2009) M. Fulciniti et al. BLOOD
- Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline
- (2009) Paul G. Richardson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Getting to First Base in Proteasome Assembly
- (2009) Henrike C. Besche et al. CELL
- Multiple Myeloma Bone Marrow Niche
- (2009) Grzegorz Basak et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- The bisphosphonate zoledronic acid has antimyeloma activityin vivoby inhibition of protein prenylation
- (2009) Andreas Guenther et al. INTERNATIONAL JOURNAL OF CANCER
- Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy
- (2009) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
- (2009) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Is the international staging system superior to the Durie–Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant
- (2009) P N Hari et al. LEUKEMIA
- Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
- (2009) C B Reeder et al. LEUKEMIA
- Breaking the chains: structure and function of the deubiquitinases
- (2009) David Komander et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
- (2009) Michael Gnant et al. NEW ENGLAND JOURNAL OF MEDICINE
- Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
- (2009) Patrice Dubreuil et al. PLoS One
- Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis
- (2008) Shaji K. Kumar et al. AMERICAN JOURNAL OF HEMATOLOGY
- Comparison of Twin and Autologous Transplants for Multiple Myeloma
- (2008) Asad Bashey et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Multiple myeloma
- (2008) R. A. Kyle et al. BLOOD
- Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
- (2008) B. Barlogie et al. BLOOD
- Aplidin, a Marine Organism-Derived Compound with Potent Antimyeloma Activity In vitro and In vivo
- (2008) C. S. Mitsiades et al. CANCER RESEARCH
- Mechanisms of proteasome inhibitor action and resistance in cancer
- (2008) David J. McConkey et al. DRUG RESISTANCE UPDATES
- Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study
- (2008) Asher Chanan-Khan et al. JOURNAL OF CLINICAL ONCOLOGY
- Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma
- (2008) T Stühmer et al. LEUKEMIA
- IRF4 addiction in multiple myeloma
- (2008) Arthur L. Shaffer et al. NATURE
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI)
- (2008) T. G. Gleeson et al. SKELETAL RADIOLOGY
- Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
- (2007) A. Dispenzieri et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started